UK Markets closed

Achilles Therapeutics plc (ACHL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.33-0.27 (-4.82%)
At close: 4:00PM EST
Sign in to post a message.
  • p
    pjtrader
    I have read the report a few times and still cant really understand why the market isn't liking it...
  • J
    James
    The company shared initial data from its Material Acquisition Platform, highlighting the ability of its proprietary VELOS manufacturing process to extract personalised cell therapy candidates across several solid tumour types.

    Disclosed as part of a presentation at the ESGCT Congress, the data read included 74 patient samples that were processed at the time of submission. In line with publicly available data, its PELEUS platform has identified 107 clonal neoantigens in NSCLC samples, 156 in melanoma samples, and 71 in head and neck squamous cell carcinoma samples. The collection of patient material is currently underway across eight sites in the U.K., EU, and the U.S.
  • A
    Aiden
    This stock is about to break out soon to 20ish
  • A
    Aaron
    This is trading at <70% value of just its cash on hand.....what is going on....
  • p
    pjtrader
    All I can do is chalk it up as tax loss harvesting....if I didn't already average down on this move, I might have considered it to...:-)
  • Y
    Yahoo Finance Insights
    Achilles Therapeutics reached an all time low at 4.60
  • Y
    Yahoo Finance Insights
    Achilles Therapeutics reached an all time low at 4.60
  • Y
    Yahoo Finance Insights
    Achilles Therapeutics reached an all time low at 4.85
  • Y
    Yahoo Finance Insights
    Achilles Therapeutics reached an all time low at 4.85
  • Y
    Yahoo Finance Insights
    Achilles Therapeutics reached an all time low at 5.35
  • Y
    Yahoo Finance Insights
    Achilles Therapeutics reached an all time low at 5.23
  • J
    James
    Next clinical data will be presented at SITC.
  • E
    Erik
    They made a point in saying their potency tests might be better than IOVA's in their call. Though long IOVA, if so, they may have some decent runway.
  • Y
    Yahoo Finance Insights
    Achilles Therapeutics is down 12.30% to 6.42
  • J
    James
    This year there will be interim data from ten patients, first patient will dosed in the combo trials, they will enrol the first patient in the US, an IND will be filed for HNSCC, and Catapult manufacturing will come on-line.
  • J
    James
    The primary objective of this trial is to assess the safety and tolerability of cNeT as monotherapy and in combination with pembrolizumab, and also evaluate the clinical efficacy as a secondary measure. Additional data evaluating cNeT persistence, phenotype, and functionality will be reviewed while also exploring potential biomarkers of clinical activity and factors affecting response. This will include analysis of patient samples using a bespoke plasma ctDNA assay.''With 75% of patients with NSCLC presenting with inoperable or metastatic disease and a 5-year survival for stage IV disease as low #$%$, additional treatments are needed for this large patient population including autologous cell therapies like Achilles? cNeT,'' commented Dr. Jamal-Hanjani. ''The rationale of the trial is very evident as we know that NSCLC patients with tumours that have a high burden of clonal neoantigens have improved disease free survival and increased sensitivity to checkpoint inhibition.''''Just as with our melanoma trial, this allows us to look at the safety and tolerability of our precision cNeT as monotherapy and in combination with a checkpoint inhibitor,'' said Dr. Peggs, CMO of Achilles. ''While the primary purpose of the trials is safety, the addition of these checkpoint combination cohorts will allow further examination of T cell kinetics and the contribution of cell dose and checkpoint therapy to treatment outcomes. Further, we will continue to look at the predictive value of ctDNA as a potential marker for clinical events as we look towards the future of our product with potential companion diagnostics in addition to our planned potency assays.''https://ir.achillestx.com/static-files/645c95d7-bdbe-438a-9ca2-98b57e680123
  • p
    pjtrader
    Now they are saying its a buy with a 27 dollar target...go figure :-)
  • B
    Blockbuster
    ETTX much better gem than ACHL ..2xBIG PHASE 3 readouts IMMINENT

    (ETTX) $2.48 --2x BIG Phase 3 Drugs with readout in October = Next 1000%++opp guys

    "Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam--- – Phase 3 top-line data readout now anticipated in early 4Q 2021 –---
  • C
    Chari
    Very small float. Being played.
  • J
    James
    Interim analysis on ten patients across the two trials is expected in Q4, the first PD-1 combination trial (in melanoma) should start then, and so should the higher median doses* to recruitment.

    * With VELOS Process one (used now), T-cells and harvested from the tumour and DCs are loaded with clonal peptides, activate and this drives cNet expansion. For Process two, additional cytokines (undisclosed) boost the harvest of tumour reactive T-cells and an optimised DC-driven co-culture followed by short T-cell boost increases the final cNeT dose.